News

Beactica participates in EU training network on fragment-based drug discovery

Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a Marie Curie Initial Training Network (ITN). The ITN, called FRAGNET, is funded with 3.9 MEUR by the EU and aims to deliver 15 skilled early-stage researchers in the field of fragment-based drug discovery (FBDD).“Training... [...]

Beactica announces appointment of Scientific Advisors

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Professor Jan Kihlberg and Dr Vendela Parrow as Scientific Advisors. They will, together with company co-founder Professor Helena Danielson, assist the progression of Beactica’s internal drug discovery programs within oncology... [...]

Beactica Appoints Dr Ulf Bremberg as Chief Scientific Officer

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Dr Ulf Bremberg as Chief Scientific Officer. "We are delighted to have Ulf join Beactica at an important time for the company.” said Dr Per Källblad, CEO of Beactica. "As our internal pipeline is advancing, the appointment... [...]

Beactica expands into new premises

Beactica, the Swedish fragment-based drug discovery company, today announced its move into new premises at the Uppsala Business Park. "The move to the new premises give us excellent opportunities to expand as the company grows.” said Beactica’s COO, Dr Malin Elinder. "Our international collaboration partners will... [...]

Beactica scientists publish strategies for discovery of allosteric modulators

Beactica, the Swedish fragment-based drug discovery company, today announced the publication of a key paper in Proceedings of the National Academy of Sciences*. The paper describes important work towards the discovery of novel drugs targeting ligand-gated ion channels, a significant family of drug targets involved in... [...]

Beactica awarded funding to develop epigenetic cancer drugs

Beactica, the Swedish fragment-based drug discovery company, today announced that it has been awarded a SEK 3.0 million grant from the Swedish Governmental Agency for Innovation Systems (VINNOVA). The grant will be used to support the development of a new epigenetic drug for treatment of cancer. Specifically, the... [...]

Beactica appoints Magnus Björsne to its Board of Directors

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Dr Magnus Björsne to its Board of Directors. Dr Björsne, Executive Director at AstraZeneca BioVentureHub, brings more than 15 years of experience from the pharmaceutical industry to the Company. "We are delighted to welcome... [...]